Cyclic nucleotide-gated channel alpha 3

AGTC Launches Nationwide Mobile Vision Testing Program for Patients Enrolled in Its Ongoing Phase 1/2 Clinical Trials

Retrieved on: 
Monday, June 15, 2020
Vision, Perception, Channelopathies, Health, Ion channels, Agnosía, Cyclic nucleotide-gated channel alpha 3, Achromatopsia, Retinitis pigmentosa, Cyclic nucleotide gated channel beta 3, Retinitis, Clinical trial

By using a creative patient focused approach to testing via our mobile vision testing program, we take the test to the patient to support their needs during this extremely difficult time.

Key Points: 
  • By using a creative patient focused approach to testing via our mobile vision testing program, we take the test to the patient to support their needs during this extremely difficult time.
  • The mobile vision testing program is available to patients enrolled in AGTCs clinical trials across the United States with up-coming scheduled visits for those who want to maintain their follow-up study assessments while restrictions remain in effect due to COVID-19.
  • AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3).
  • AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

AGTC Announces Publication of Positive Preclinical Data that Provides Foundational Scientific Evidence for its Ongoing Clinical Program in Patients with X-Linked Retinitis Pigmentosa (XLRP)

Retrieved on: 
Wednesday, May 20, 2020
Vision, Perception, Channelopathies, Senses, Ion channels, Blindness, RTT, Retinitis pigmentosa, Cyclic nucleotide-gated channel alpha 3, Retinitis, Achromatopsia, Cyclic nucleotide gated channel beta 3

The data presented to date from our ongoing Phase 1/2 clinical program in XLRP using rAAV2tYF-GRK1-hRPGRco demonstrate the power of patent-protected technology platform.

Key Points: 
  • The data presented to date from our ongoing Phase 1/2 clinical program in XLRP using rAAV2tYF-GRK1-hRPGRco demonstrate the power of patent-protected technology platform.
  • In January 2020, AGTC announced positive interim six-month data from its ongoing Phase 1/2 clinical program in XLRP.
  • Dose range finding studies with two RPGR transgenes in a canine model of X-linked retinitis pigmentosa treated with subretinal gene therapy.
  • AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3).

AGTC Announces Completion of Enrollment in the Two Highest Dose Groups of its Ongoing Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosa

Retrieved on: 
Wednesday, February 19, 2020
Branches of biology, Vision, Perception, Channelopathies, Ion channels, Achromatopsia, Agnosía, Visual perception, Visual system, Cyclic nucleotide-gated channel alpha 3, Gene therapy, Retinitis

The patients in these additional groups received a higher or highest dose of AGTCs XLRP candidate.

Key Points: 
  • The patients in these additional groups received a higher or highest dose of AGTCs XLRP candidate.
  • AGTC most recently reported data from the ongoing XLRP Phase 1/2 clinical trial in January 2020 .
  • AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases.
  • Its initial focus is in the field of ophthalmology, where it has active clinical trial programs in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 & ACHM CNGA3).

AGTC to Host Conference Call and Webcast on January 23 at 8:00 am ET to Discuss Achromatopsia Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials

Retrieved on: 
Wednesday, January 22, 2020
Vision, Perception, Ion channels, Channelopathies, Senses, Cyclic nucleotide-gated channel alpha 3, Achromatopsia, Retinitis pigmentosa, Cyclic nucleotide gated channel beta 3

AGTC management will host a conference call and webcast with accompanying slides to review the data beginning at 8:00 a.m. Eastern time on the same date.

Key Points: 
  • AGTC management will host a conference call and webcast with accompanying slides to review the data beginning at 8:00 a.m. Eastern time on the same date.
  • The live webcast will be available in the Events and Presentations section of the Investor Relations page at http://ir.agtc.com/events-and-presentations .
  • The archived webcast and slide presentation will be available in the Events and Presentations section of the Company's website.
  • Its initial focus is in the field of ophthalmology, in which it has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 & ACHM CNGA3).

AGTC to Host Conference Call and Webcast on January 9 at 8:00 am ET to Discuss X-Linked Retinitis Pigmentosa Interim Six-Month Data from the Dose Expansion Cohort of its Ongoing Phase 1/2 Clinical Trial

Retrieved on: 
Wednesday, January 8, 2020
Vision, Perception, Ion channels, Channelopathies, Senses, Cyclic nucleotide-gated channel alpha 3, Achromatopsia, Retinitis pigmentosa, Cyclic nucleotide gated channel beta 3

AGTC management will host a conference call and webcast with accompanying slides to review the data beginning at 8:00am Eastern Time on the same date.

Key Points: 
  • AGTC management will host a conference call and webcast with accompanying slides to review the data beginning at 8:00am Eastern Time on the same date.
  • The live webcast will be available in the Events and Presentations section of the Investor Relations page at http://ir.agtc.com/events-and-presentations .
  • The archived webcast and slide presentation will be available in the Events and Presentations section of the Company's website.
  • Its initial focus is in the field of ophthalmology, in which it has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 & ACHM CNGA3).